There is limited experience with overdose of LINZESS. During the clinical development program of LINZESS, single doses of 2897 mcg were administered to 22 healthy volunteers; the safety profile in these subjects was consistent with that in the overall LINZESS-treated population, with diarrhea being the most commonly reported adverse reaction.

LINZESS is contraindicated in:

• Pediatric patients up to 6 years of age [see WARNINGS AND PRECAUTIONS, Use In Specific Populations and Nonclinical Toxicology]
• Patients with known or suspected mechanical gastrointestinal obstruction

Last reviewed on RxList: 9/7/2012
This monograph has been modified to include the generic and brand name in many instances.